Table 5.
Exampled output for rheumatoid arthritis with ranking scores and sample source sentences.
| CUI | Concept | Semantic type | Occurrence | Interest | DC | WDC | Source sentences |
|---|---|---|---|---|---|---|---|
| C0025677 | Methotrexate | Phsu | 4102 | 0.3095 | 394 | 1271.29 | CONCLUSIONS: This study confirms previous observations from a dose-ranging study showing that anakinra, in combination with MTX, is an effective and safe treatment for patients with RA who have inadequate responses to MTX alone |
| C0666743 | Infliximab | Phsu | 1974 | 0.1724 | 212 | 646.91 | Infliximab therapy was also associated with improvements in health-related quality of life in patients with Crohn’s disease or rheumatoid arthritis |
| C0717758 | Etanercept | Aapp | 1313 | 0.1263 | 148 | 440.82 | CONCLUSION: Etanercept as monotherapy was safe and was superior to MTX in reducing disease activity, arresting structural damage, and decreasing disability over 2 years in patients with early, aggressive RA |
| C0242708 | Antirheumatic Drugs, Disease-Modifying | Phsu | 940 | 0.1002 | 158 | 385.38 | Early diagnosis and treatment with disease-modifying antirheumatic drugs (DMARDs) are necessary to reduce early joint damage, functional loss, and mortality |
| C0393022 | Rituximab | Aapp | 1004 | 0.0844 | 125 | 354.26 | CONCLUSIONS: Evidence from RCTs suggests that RTX and ABT are more effective than supportive care |
DC = degree centrality; WDC = weighted degree centrality; phsu = pharmaceutical substance; aapp = amino acid, peptide, or protein; MTX = methotrexate; RA = rheumatoid arthritis; RTX = rituximab; ABT = abatacept; RCTs = randomised controlled trials.